Clinical Trial Update: Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating androgen deprivation therapy with or without Radium-223 dichloride in metastatic prostate cancer with bone metastases; study terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases
• Prostate Cancer

Drugs mentioned

• Androgen deprivation therapy (Androgen deprivation therapy)
• Radium-223 dichloride (radium-223 dichloride)

Snippet

Sponsor: Ajjai Alva, MD | Conditions: Prostate Cancer, Bone Metastases | Phase 2 | Status: TERMINATED | Results posted: 2019-07-09